Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep156 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

What should be the cut–off age for active screening for type 2 diabetes in Uzbekistan?

Alieva Anna , Ismailov Saydiganikhodja , Rakhimova Gulnara

Background: Different screening programs recommend starting active search for type 2 diabetes (DM2) at age from 35 to 45. This difference comes from variety in structure of population and weight of age as a risk factor, and also has economical background.The aim of our study: Was to find out the most acceptable cut–off age for DM2 screening in Uzbekistan.Material and Methods: We analyzed results of type 2 diabetes screening i...

ea0070ep474 | Thyroid | ECE2020

Association of the rs12976445 MIR125A polymorphism with the clinical course of Graves’ disease in Russian population

Peikrishvili Natalia , Volkova Anna , Dora Svetlana

Introduction: Graves’ disease (GD) is an autoimmune disorder of the thyroid gland, which is characterisied by a breakdown in immune tolerance. The lymphocytic infiltration of the thyroid leads to production of autioantibodies targeting thyroid stimulating hormone receptor (TSHR). The clinical course of GD varies among patients and it is difficult to predict the relapse risk after antithyroid therapy withdrawal. It is believed that GD occurs due to genetic suspectibility ...

ea0032p394 | Diabetes | ECE2013

Leptin and other adipocins in patients with type 2 diabetes

Verbovoy Andrey , Solomonova Elena , Pashenceva Anna

Aim: To evaluate leptin and other adipocins content in the blood with type 2 diabetes.Materials and methods: Eighty six patients with type 2 diabetes were examined (59 women and 27 men) middle-aged 58.6±1.04 years old. The control group included 16 patients (eight women and eight men) middle-aged 22.6±0.6 years old. The HOMA-IR, insulin, adiponectin, resistin, leptin, and omentin levels were investigated.Results: In patie...

ea0031p197 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2013

DPPIV and macronutrients regulate the expression of PYY3–36 in human gut epithelial cells

Kosicka Anna , Renshaw Derek , Zariwala Mohammed Gulrez

The enzyme dipeptidyl peptidase-IV (DPP-IV) is expressed by gut epithelial cells. DPP-IV cleaves X-proline dipeptides from the N-terminus of polypeptide hormones including GLP-1, GIP and PYY. DPP-IV causes a deactivation of the incretin hormones GLP-1 and GIP, whereas conversely, by converting PYY1–36 to PYY3–36 it allows specific activation of the Y2 receptors in the arcuate nucleus of the hypothalamus leading to hypophagia. Infused PYY3–36 has been ...

ea0028p97 | Clinical practice/governance and case reports | SFEBES2012

Unusual presentation, multi speciality effort and excellent outcome – A case of ovarian carcinoid

Mathew Anna , Katreddy Venkata , Buch Harit

Carcinoid tumours are the commonest neuroendocrine tumours (50%), with a prevalence of 3–5/100,000. 10% present with carcinoid syndrome due to release of kinins and serotonin, released directly from the tumour in to the blood or due to liver metastases. Carcinoid heart disease due to ovarian carcinoid is extremely rare. Here we present such a case. A 69 year old female presented to surgeons with increased bowel frequency and weight loss. Blood tests, colonoscopy and biops...

ea0028p121 | Clinical practice/governance and case reports | SFEBES2012

T3 a life saver

Chahal Harvinder , Hawkins Anna , Nikookam Kash

We report a case of a female patient who presented aged 37yr with tiredness, weight gain and oligomenorrhea. Biochemically she was diagnosed with primary hypothyroidism with a TSH 10.9 mu/L and free-T4 8.2 pmol/L (10.5–22.0); she was commenced onto Thyroxine 50 mcg once a day (OD). Six months later her thyroid function tests improved with a TSH 2.2 mu/L and free-T4 13.0 pmol/L, however she felt her symptoms had worsened. The dose of thyroxine was increased to 75 mcg OD. ...

ea0028p261 | Pituitary | SFEBES2012

Improving local services: using objective measures to determine levels of psychosocial need in pituitary patients

Jackson Sue , Pay Charlotte , Crown Anna

Introduction: In 2005, an explorative study was undertaken on behalf of the Pituitary Foundation (PF) to assess the psychosocial impact of living with a pituitary condition. The study found high levels of psychosocial distress among patients resulting in reduced quality of life (QoL). Improving QoL is central to the National Institute for Clinical Excellence guidance on improving outcomes for pituitary patients. The aim of this study was to utilise the same measures of psychos...

ea0028p268 | Pituitary | SFEBES2012

Local v National - comparing results of a 2010 local survey on pituitary patients’ satisfaction with information and support from healthcare professionals to 2008 nationwide survey data

Jackson Sue , Baker Daniel , Crown Anna

Introduction: Pituitary conditions are rare and diagnosis may be slow because symptoms are ambiguous. The treatment may be a combination of surgery, radiotherapy and medication so patients see many healthcare professionals. This survey sought to assess patient satisfaction with the information and support they receive from GPs, endocrinologists, neurosurgeons, radiotherapists, specialist nurses, and other agencies (e.g. Pituitary Foundation (PF)).Method:...

ea0025s4.3 | Endocrine regulation of ageing | SFEBES2011

Cortisol, DHEAS and immunesenescence

Lord Janet , Phillips Anna , Arlt Wiebke

Normal ageing is accompanied by increased organismal frailty, reflecting organ specific functional decline, with an associated increase in the likelihood of disease. The immune system undergoes significant decline with age, termed immunesenescence, which results in increased susceptibility to infection and reduced vaccination responses. Significant changes in the hormonal milieu also occur with age and it is clear that age-related changes in adrenal hormone secretion can impos...

ea0022p586 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Effect of octreotide LAR on the volume of pituitary adenoma in acromegalic patients

Krzentowska Anna , Baldys-Waligorska Agata , Golkowski Filip

We evaluated the volume of pituitary adenoma in patients treated with ocreotide LAR (SSLAR) prior to surgery.Materials and methods: Twenty-six patients (22 females and 4 males, mean age 57.5±15.0 years) were treated with SSLAR: 5 patients with microadenoma – during 6 months, and 21 patients with macroadenoma – during 12 months before surgery, as recommended by the Polish Society of Endocrinology. Concentration of hGH and IGF1 was evaluated...